title: Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.
abstract: Amyloid imaging with (18)F-labeled radiotracers will allow widespread use, facilitating research, diagnosis, and therapeutic development for Alzheimer disease. The purpose of the study program was to compare cortical amyloid deposition using (18)F-florbetaben and PET in controls and subjects with mild cognitive impairment (MCI), frontotemporal lobar degeneration (FTLD), dementia with Lewy bodies (DLB), vascular dementia (VaD), Parkinson disease (PD), and Alzheimer disease (AD).
  
  
  METHODS
  One hundred nine subjects in 3 clinical studies at Austin Health were reviewed: 32 controls, 20 subjects with MCI, and 30 patients with AD, 11 with FTLD, 7 with DLB, 5 with PD, and 4 with VaD underwent PET after intravenous injection of 300 MBq of (18)F-florbetaben. Standardized uptake value ratios (SUVR) using the cerebellar cortex as a reference region were calculated between 90 and 110 min after injection.
  
  
  RESULTS
  When compared with the other groups, AD patients demonstrated significantly higher SUVRs (P < 0.0001) in neocortical areas. Most AD patients (96%) and 60% of MCI subjects showed diffuse cortical (18)F-florbetaben retention. In contrast, only 9% of FTLD, 25% of VaD, 29% of DLB, and no PD patients and 16% of controls showed cortical binding. Although there was a correlation between Mini Mental State Examination and β-amyloid burden in the MCI group, no correlation was observed in controls, FTLD or AD.
  
  
  CONCLUSIONS
  (18)F-florbetaben had high sensitivity for AD, clearly distinguished patients with FTLD from AD, and provided results comparable to those reported with (11)C-Pittsburgh Compound B in a variety of neurodegenerative diseases.
authors.affiliation: Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia. villemagne@petnm.unimelb.edu.au
authors.forename: Victor L
authors.initials: VL
authors.lastname: Villemagne
authors.forename: Kevin
authors.initials: K
authors.lastname: Ong
authors.forename: Rachel S
authors.initials: RS
authors.lastname: Mulligan
authors.forename: Gerhard
authors.initials: G
authors.lastname: Holl
authors.forename: Svetlana
authors.initials: S
authors.lastname: Pejoska
authors.forename: Gareth
authors.initials: G
authors.lastname: Jones
authors.forename: Graeme
authors.initials: G
authors.lastname: O'Keefe
authors.forename: Uwe
authors.initials: U
authors.lastname: Ackerman
authors.forename: Henri
authors.initials: H
authors.lastname: Tochon-Danguy
authors.forename: J Gordon
authors.initials: JG
authors.lastname: Chan
authors.forename: Cornelia B
authors.initials: CB
authors.lastname: Reininger
authors.forename: Lueder
authors.initials: L
authors.lastname: Fels
authors.forename: Barbara
authors.initials: B
authors.lastname: Putz
authors.forename: Beate
authors.initials: B
authors.lastname: Rohde
authors.forename: Colin L
authors.initials: CL
authors.lastname: Masters
authors.forename: Christopher C
authors.initials: CC
authors.lastname: Rowe
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000000981:diagnostic imaging*; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000814:Aniline Compounds / Q000494:pharmacology*; D016022:Case-Control Studies; D002531:Cerebellum / Q000000981:diagnostic imaging; D003704:Dementia / Q000000981:diagnostic imaging*; D005260:Female; D005462:Fluorine Radioisotopes / Q000494:pharmacology*; D057180:Frontotemporal Dementia / Q000000981:diagnostic imaging; D006801:Humans; D007091:Image Processing, Computer-Assisted; D016631:Lewy Bodies / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D019636:Neurodegenerative Diseases / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography / Q000379:methods; D011868:Radioisotopes / Q000494:pharmacology; D013267:Stilbenes / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D016229:Amyloid beta-Peptides; D000814:Aniline Compounds; D005462:Fluorine Radioisotopes; D011868:Radioisotopes; D013267:Stilbenes; C527756:4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene